Article

Hepatitis screening not useful for patients with polyarthritis

The seroprevalence of hepatitis is no higher in patients with recent-onset polyarthritis than in the general population. Therefore, screening patients for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection when evaluating them for polyarthritis suggestive of rheumatoid arthritis (RA) is not useful.

The seroprevalence of hepatitis is no higher in patients with recent-onset polyarthritis than in the general population. Therefore, screening patients for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection when evaluating them for polyarthritis suggestive of rheumatoid arthritis (RA) is not useful.

Guennoc and colleagues investigated a longitudinal, prospective cohort of 813 patients for anti-HCV antibodies and HBs antigen. The baseline assessment included a standardized interview, a general physical examination, laboratory tests, and radiographs.

The seroprevalences of HCV and HBV infection in the cohort were 0.86% and 0.12%, respectively, similar to the values reported in the general population. The chemiluminescent microparticle immunoassay result was positive in 16 patients with HCV infection. In this group, the confirmation immunoblot test result was positive in 7 patients, negative in 7, and indeterminate (ultimately negative) in 2. Four of the 7 immunoblot-positive patients had received a diagnosis of HCV-related arthritis. Patients with HCV infection had elevated serum transaminase levels, but only 2 had levels that exceeded 40 IU. Only 1 patient had HBV infection.

The authors noted that knowing which infections are unnecessary to investigate would be helpful.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.